Hematopoietic Stem Cell TransplantationTransplantation, AutologousBone Marrow TransplantationHematopoietic Stem CellsTransplantation ConditioningTransplantation, HomologousStem CellsPeripheral Blood Stem Cell TransplantationStem Cell TransplantationHematologic NeoplasmsGraft vs Host DiseaseMultiple MyelomaTreatment OutcomeMelphalanCombined Modality TherapyBone MarrowAdult Stem CellsBone Marrow CellsWhole-Body IrradiationDisease-Free SurvivalRetrospective StudiesEmbryonic Stem CellsLymphoma, Non-HodgkinGraft SurvivalCell DifferentiationTransplantation ChimeraSurvival RateCyclophosphamideMyeloablative AgonistsTissue DonorsAntigens, CD34RecurrenceRemission InductionHematopoietic Stem Cell MobilizationLeukemiaBusulfanHematopoiesisHistocompatibility TestingImmunosuppressive AgentsLiver TransplantationHistocompatibilitySalvage TherapySurvival AnalysisAnemia, AplasticCord Blood Stem Cell TransplantationMesenchymal Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsStem Cell NicheMice, Inbred C57BLLeukemia, Myeloid, AcuteTime FactorsCell LineageTransplantation, IsogeneicPluripotent Stem CellsGraft vs Leukemia EffectHepatic Veno-Occlusive DiseaseKidney TransplantationChimerismBone and BonesHematologic DiseasesHLA AntigensColony-Forming Units AssayFlow CytometryTransplantation ImmunologyMyelodysplastic SyndromesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMesenchymal Stromal CellsBone Marrow PurgingPrognosisCell TransplantationCells, CulturedPrecursor Cell Lymphoblastic Leukemia-LymphomaMultipotent Stem CellsSevere Combined ImmunodeficiencyStem Cell FactorNeural Stem CellsGraft vs Tumor EffectLymphocyte TransfusionGraft RejectionInduced Pluripotent Stem CellsT-LymphocytesGranulocyte Colony-Stimulating FactorLymphocyte DepletionAcute DiseaseCell SeparationAntineoplastic AgentsImmunosuppressionLeukemia, MyeloidRadiation ChimeraCell ProliferationBone Marrow DiseasesCytomegalovirus InfectionsFollow-Up StudiesSiblingsHeart TransplantationVidarabineFetal BloodAntilymphocyte SerumUnrelated DonorsCytarabine